The blog

News & Updates

Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.

All Retatrutide BPC-157 TB-500 GHK-Cu Human Growth Hormone Tesamorelin Semax Selank Epithalon NAD+SS-31 SLU-PP-332

12 September 2026 · nad-plus · nmn · nicotinamide-riboside · research · tga

NMN vs NR: The 2026 Head-to-Head NAD+ Trials Disagree

Two 2026 trials compared NMN, NR and nicotinamide head-to-head. What the NAD+ research really shows, the gut-microbe twist, and the rules in Australia.

9 September 2026 · nad-plus · nmn · nicotinamide-riboside · longevity · tga

NAD+ Research: The Biomarker Goes Up, Outcomes Lag

NAD+ research in 2026: a 113-study review found NMN and NR reliably raise NAD+ levels, but functional outcomes stay mixed. Plus the NAD+ Australia TGA rules.

Stay informed

Be first to know.
When it reaches Australia.

Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:

The latest clinical trial results and news from Eli Lilly
Updates on TGA regulatory progress in Australia
How and where to access Retatrutide when it becomes available
Occasional information from retatrutide.net.au and our affiliated partners

TGA review expected 2027 — subscribers hear the moment the status changes.

Get the free guide + updates

Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.

News & Updates

NMN vs NR: The 2026 Head-to-Head NAD+ Trials Disagree

NAD+ Research: The Biomarker Goes Up, Outcomes Lag

Be first to know.When it reaches Australia.

Be first to know.
When it reaches Australia.